Researchers have discovered that a protein called cardiotrophin 1 (CT1) can trick the heart into growing in a healthy way and pumping more blood, just as it does in response to exercise and pregnancy. They show that this good kind of heart growth is very different from the harmful enlargement of the heart that occurs during heart failure. They also show that CT1 can repair heart damage and improve blood flow in animal models of heart failure.
The results are published in Cell Research. The research team is from The Ottawa Hospital, the University of Ottawa, the University of Ottawa Heart Institute and Carleton University.
Heart failure is a leading cause of death and disability in high-income countries and a growing problem around the world. It occurs when the heart can’t pump enough blood through the body, often because a heart attack has damaged the heart muscle tissue.
“When part of the heart dies, the remaining muscles try to adapt by getting bigger, but this happens in a dysfunctional way and it doesn’t actually help the heart pump more blood,” said Dr. Lynn Megeney, senior author of the study and a senior scientist at The Ottawa Hospital and professor at the University of Ottawa. “We found that CT1 causes heart muscles to grow in a more healthy way and it also stimulates blood vessel growth in the heart. This actually increases the heart’s ability to pump blood, just like what you would see with exercise and pregnancy.”
Dr. Megeney and his colleagues conducted a variety of studies in mice, rats and cells growing in the lab. In addition to CT-1, some of the studies involved a drug called phenylephrine (PE), which is known to cause the bad kind of heart growth. They found:
• Heart muscle cells treated with CT-1 become longer, healthier fibres, while those treated with PE just grow wider.
• CT-1 causes blood vessels to grow alongside the new heart muscle tissue and increases the heart’s ability to pump blood, while PE does neither.
• When CT-1 treatment stops, the heart goes back to its original condition, just like it does when exercise or pregnancy end. However, the dysfunctional heart growth caused by PE is irreversible.
• CT-1 dramatically improves heart function in two animal models of heart failure – one caused by a heart attack (affecting the left side of the heart) and one caused by high blood pressure in the lungs (pulmonary hypertension, affecting the right side of the heart).
• Both CT-1 and PE stimulate heart muscle growth through a molecular pathway that has traditionally been associated with promoting cell suicide (apoptosis), but CT-1 has a better ability to control this pathway.
“This experimental therapy is very exciting, particularly because it shows promise in treating both left and right heart failure,” said Dr. Duncan Stewart, a cardiologist, senior scientist and co-senior author on the paper who is also Executive Vice-President of Research at The Ottawa Hospital and a professor at the University of Ottawa. “Currently, the only treatment for right heart failure is a transplant. And although we have drugs that can reduce the symptoms of left heart failure, we can’t fix the problem, and left heart failure often leads to right heart failure over time.”
“An intriguing aspect of this research was how human CT1 was able to promote a healthy growth response in multiple animal models,” said co-author Dr. Patrick Burgon, scientist at the University of Ottawa Heart Institute and assistant professor at the University of Ottawa. “This suggests the action of CT1 is universally conserved and puts us much closer to therapy.”
The researchers also note that while exercise could theoretically have the same benefits as CT-1, people with heart failure are usually limited in their ability to exercise.
Dr. Megeney and Dr. Stewart have patents pending for the use of CT-1 to treat heart conditions and they hope to develop partnerships to test this protein in patients. If this testing is successful it will take a number of years for the treatment to become widely available.
The Latest on: Heart failure
In-depth study Congestive Heart Failure (CHF) Treatment Devices Market, Strategy Resources, Manufacturers, Supply and Forecast to 2023
on July 12, 2018 at 12:47 am
Research N Reports has as of late declared the expansion of another exploration answer to its escalating storehouse. The exploration report, titled Congestive Heart Failure (CHF) Treatment Market," of... […]
Valvular heart disease common, has multiple treatments
on July 11, 2018 at 10:16 pm
Over the last year, I have written about coronary artery disease, congestive heart failure, cardiac arrhythmias, cardiac medications and the importance of risk factor modification in the prevention of ... […]
Exercise among best ways to reduce heart disease, researchers say
on July 11, 2018 at 9:51 pm
Heart disease is the leading cause of death for men and women in the U.S., killing 600,000 Americans every year. But there are ways to prevent this dangerous health threat. Researchers found that men ... […]
8 Tips for Staying Safe at Home With Heart Failure
on July 11, 2018 at 5:57 pm
Heart failure sounds scary, and it’s a serious condition that requires a doctor’s care, but it doesn’t mean your heart has stopped or failed. Heart failure (HF) means your heart doesn’t pump enough bl... […]
Genetic Role in Heart Failure Seen in Adoption Study
on July 11, 2018 at 12:33 pm
Heart failure may be moderately heritable, according to a study of families involved with adoption. In a Swedish cohort, the risk of heart failure was higher for adoptees whose biological parents had ... […]
Global Acute Heart Failure (AHF) Therapeutics Strategic Business Opportunity Outlook 2018-2022 - Novel Treatments Offer a Ray of Hope - ResearchAndMarkets.com
on July 11, 2018 at 11:03 am
DUBLIN--(BUSINESS WIRE)--The "Acute Heart Failure (AHF) Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The report provides separate compre... […]
Global Acute Heart Failure (AHF) Therapeutics Market 2015-2022: Strategic Business Report 2018 - Market Drivers, Trends & Issues
on July 11, 2018 at 11:03 am
The "Acute Heart Failure (AHF) Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The report provides separate comprehensive analytics for the ... […]
Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
on July 11, 2018 at 8:31 am
FDA approval for HVAD implantation via thoracotomy is based on data from the LATERAL prospective clinical trial, in which 144 patients, with end-stage heart failure who were eligible for heart transpl... […]
The two Americas of cardiovascular care: Heart disease is becoming a big red state problem
on July 11, 2018 at 7:30 am
Heart disease is the No. 1 killer in the United States. Reduced smoking, a focus on nutrition, preventative medicine and access to cholesterol-lowering drugs, like Lipitor, all have contributed to a s... […]
Heart disease can be catastrophic for financial health
on July 11, 2018 at 4:08 am
It’s a painful double-whammy: Every year in the United States, nearly 2 million low-income families dealing with coronary artery disease face soaring or “catastrophic” out-of-pocket financial burdens, ... […]
via Google News and Bing News